Management of the hereditary coagulation disorders.
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000151:congenital / Q000235:genetics*; D001779:Blood Coagulation Factors; D002543:Cerebral Hemorrhage / Q000628:therapy; D002744:Chlorpheniramine / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004322:Drainage; D005169:Factor VIII / Q000096:biosynthesis / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000628:therapy; D006395:Hemarthrosis / Q000628:therapy; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy*; D006487:Hemostasis; D006509:Hepatitis B / Q000209:etiology; D006801:Humans; D006967:Hypersensitivity / Q000517:prevention & control; D007592:Joint Diseases / Q000150:complications / Q000601:surgery; D006472:Oral Hemorrhage / Q000628:therapy; D013154:Spleen / Q000637:transplantation; D014081:Tooth Extraction / Q000009:adverse effects; D065227:Transfusion Reaction; D014842:von Willebrand Diseases / Q000628:therapy*
D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D002744:Chlorpheniramine; D004155:Diphenhydramine; D005169:Factor VIII